<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03029715</url>
  </required_header>
  <id_info>
    <org_study_id>MenoufiaU2016/2</org_study_id>
    <nct_id>NCT03029715</nct_id>
  </id_info>
  <brief_title>Anaesthesia for Laparoscopic Sleeve Gastrectomy</brief_title>
  <official_title>Comparative Study Between Inhalational Anaesthesia and Total Intravenous Anaesthesia (TIVA) With Dexmedetomidine for Morbidly Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Laparoscopic sleeve gastrectomy is commonly done with total intravenous&#xD;
      anaesthesia (TIVA) or balanced anaesthesia using intravenous and an inhalation agent. It is&#xD;
      still unclear which anaesthesia regimen is better for this group of patients. The present&#xD;
      study was carried out to compare the use of inhalation anaesthesia technique using desflurane&#xD;
      and TIVA using propofol and dexmedetomidine.&#xD;
&#xD;
      Methods: This randomized controlled trial was carried out on 100 morbidly obese patients&#xD;
      undergoing laparoscopic sleeve gastrectomy. The patients were randomized into two equal&#xD;
      groups, inhalational group and TIVA group for anaesthesia maintenance. All patients received&#xD;
      general anaesthesia and induced with propofol, remifentanil and cis-atracurium. In inhalation&#xD;
      group, anaesthesia was maintained by desflurane in oxygen air mixture while in TIVA group&#xD;
      anaesthesia was maintained by intravenous propofol and dexmedetomidine infusion.&#xD;
      Intra-operative vital signs and anaesthesia recovery time were recorded. Post-operative&#xD;
      nausea, vomiting, pain score, analgesic consumption, the onset of bowel movement, and&#xD;
      post-anaesthetic care unit (PACU) stay were studied for both groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After obtaining the ethics committee approval of El Menoufia University hospital and the&#xD;
      informed written consent from the patients, a hundred morbidly obese patients scheduled for&#xD;
      sleeve gastrectomy were recruited for the study. Patients with history of cardiac&#xD;
      comorbidity, chronic obstructive lung disease, drug abuse, expected difficult intubation&#xD;
      patients, and patients with history of allergy to the study drugs were excluded from the&#xD;
      study. Patients from 30 to 50 years old of both sexes were randomly allocated using&#xD;
      computerized software into two groups, fifty patients in each group. Patients in inhalation&#xD;
      group received intra-operative inhalational anaesthetic while patients in TIVA group received&#xD;
      TIVA for anaesthetic maintenance.&#xD;
&#xD;
      All patients received a routine premedication with oral sodium citrate 15ml [0.3 molar&#xD;
      (1.16gm)] and intravenous (IV) 4mg ondansetron fifteen minutes before induction. Patients in&#xD;
      both groups were connected to the routine monitoring and bispectral index (BIS) upon arrival&#xD;
      to theatre. Anaesthesia induction for both groups was carried out by 0.5-1 mcg kg -1&#xD;
      remifentanil, 2-3mg kg-1 propofol, and 0.6 mg kg-1 rocuronium. Endotracheal intubation was&#xD;
      done with the appropriate tube size.&#xD;
&#xD;
      In the inhalational group, anaesthesia was maintained by desflurane in low flow oxygen air&#xD;
      mixture 60/40%. In the TIVA group, anaesthesia was maintained using propofol 8-12 mg kg-1 h-1&#xD;
      and dexmedetomidine 0.5-1ugkg-1h-1. Remifentanil infusion of 0.05-2 µg kg-¹min-¹ was&#xD;
      administered for both groups. Muscle relaxation was maintained in both groups by rocuronium&#xD;
      infusion at a rate of 10-12ug kg1min-1. Depth of anaesthesia was monitored by bispectral&#xD;
      index and anaesthetics were adjusted in both groups to obtain BIS of 40 to 60 by giving&#xD;
      boluses of 0.5ug kg-1 remifentanil. The total boluses of intra-operative remifentanil were&#xD;
      recorded. At the end of the procedure all patients received 0.6mg atropine and sugammadex&#xD;
      16mg kg-1 to reverse the effect of rocuronium. Patients were extubated and transferred to the&#xD;
      post-anaesthetic care unit (PACU).&#xD;
&#xD;
      Post-operative pain was monitored using visual analogue score (VAS) at PACU. Morphine&#xD;
      sulphate 2 to 3 mg was given if the VAS was &gt; 4. Intravenous paracetamol 1gm and/or ketorolac&#xD;
      30 mg were given eight hourly intravenously if needed (VAS ≥3). Post-operative ondansetron&#xD;
      4mg every eight hours was given if required.&#xD;
&#xD;
      Haemodynamics including heart rate and mean arterial blood pressure (MABP) were recorded as a&#xD;
      baseline and every fifteen minutes intra-operatively. Recovery time from anaesthesia using&#xD;
      Aldrete score was recorded (the time from cessation of all anesthetics until complete&#xD;
      recovery). 10 The incidence of post-operative nausea and vomiting, post-operative analgesic&#xD;
      requirements, and the duration of PACU stay were recorded. Post-operative pain assessment&#xD;
      using VAS from 0 to 10, where 0 means no pain and 10 is the worst pain the patient&#xD;
      experienced. VAS was recorded at full recovery, every 15 minutes in PACU until discharge&#xD;
      PACU. Time of onset of post-operative bowel movement was recorded.&#xD;
&#xD;
      Statistical analysis:&#xD;
&#xD;
      Sample size calculation was calculated using Graphed Instant statistics version 3. Based on&#xD;
      the previous, studies propofol was expected to produce a drop in the MABP after induction of&#xD;
      anaesthesia by about 10 mmHg with a standard deviation of 15 mmHg so by choosing level of&#xD;
      significance 0.05 and power of 90%; the calculated sample size was 48 patients so that the&#xD;
      number of patients randomized in each group was fifty patients to ensure reliable results.&#xD;
&#xD;
      Statistical analysis was done using SPSS 19 (SPSS Inc, IBM company, Chicago,USA). The&#xD;
      patients' sex, American society of anaesthetists (ASA) status and incidence of side effects&#xD;
      were analyzed using the chi-square χ2-test. Other parameters were compared using student&#xD;
      t-test. For comparisons within the same group, paired t-test was used where for comparisons&#xD;
      between groups; unpaired t-test was used. P-value less than 0.05 was considered statistically&#xD;
      significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesic Requirements.</measure>
    <time_frame>Within one hour after surgery</time_frame>
    <description>Total paracetamol consumption.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Intra-operative Mean Arterial Blood Pressure.</measure>
    <time_frame>During operation and follow-up, an average of 2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Obese</condition>
  <arm_group>
    <arm_group_label>Intravenous anaesthesia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Propofol Dexmedetomidine Remifentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhalation anaesthesia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Desflurane Remifentanil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Total intravenous anaesthesia.</description>
    <arm_group_label>Intravenous anaesthesia</arm_group_label>
    <other_name>TIVA group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Narcotics</description>
    <arm_group_label>Inhalation anaesthesia</arm_group_label>
    <arm_group_label>Intravenous anaesthesia</arm_group_label>
    <other_name>TIVA group and inhalation group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Total intravenous anaesthesia</description>
    <arm_group_label>Intravenous anaesthesia</arm_group_label>
    <other_name>TIVA group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desflurane</intervention_name>
    <description>Inhalation anaesthesia.</description>
    <arm_group_label>Inhalation anaesthesia</arm_group_label>
    <other_name>Inhalation group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Morbid obese scheduled for sleeve gastrectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients refusal and allergy to drugs used.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 14, 2017</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>August 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>Dr Ezzeldin Ibrahim</investigator_full_name>
    <investigator_title>Assistant Professor in anaesthesia, intensive care, and pain medicine.</investigator_title>
  </responsible_party>
  <keyword>Sleeve gastrectomy</keyword>
  <keyword>TIVA</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Desflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intravenous Anaesthesia</title>
          <description>Propofol Dexmedetomidine Remifentanil&#xD;
Propofol: Total intravenous anaesthesia.&#xD;
Remifentanil: Narcotics&#xD;
Dexmedetomidine: Total intravenous anaesthesia</description>
        </group>
        <group group_id="P2">
          <title>Inhalation Anaesthesia</title>
          <description>Desflurane Remifentanil&#xD;
Remifentanil: Narcotics&#xD;
Desflurane: Inhalation anaesthesia.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intravenous Anaesthesia</title>
          <description>Propofol Dexmedetomidine Remifentanil&#xD;
Propofol: Total intravenous anaesthesia.&#xD;
Remifentanil: Narcotics&#xD;
Dexmedetomidine: Total intravenous anaesthesia</description>
        </group>
        <group group_id="B2">
          <title>Inhalation Anaesthesia</title>
          <description>Desflurane Remifentanil&#xD;
Remifentanil: Narcotics&#xD;
Desflurane: Inhalation anaesthesia.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.31" spread="10.43"/>
                    <measurement group_id="B2" value="34.35" spread="11.15"/>
                    <measurement group_id="B3" value="34.83" spread="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Analgesic Requirements.</title>
        <description>Total paracetamol consumption.</description>
        <time_frame>Within one hour after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sleeve Gastrectomy 1</title>
            <description>Propofol Dexmedetomidine Remifentanil&#xD;
Propofol: Total intravenous anaesthesia.&#xD;
Remifentanil: Narcotics&#xD;
Dexmedetomidine: Total intravenous anaesthesia</description>
          </group>
          <group group_id="O2">
            <title>Sleeve Gastrectomy 2</title>
            <description>Desflurane Remifentanil&#xD;
Remifentanil: Narcotics&#xD;
Desflurane: Inhalation anaesthesia.</description>
          </group>
        </group_list>
        <measure>
          <title>Analgesic Requirements.</title>
          <description>Total paracetamol consumption.</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="1.01"/>
                    <measurement group_id="O2" value="1.67" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Intra-operative Mean Arterial Blood Pressure.</title>
        <time_frame>During operation and follow-up, an average of 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sleeve Gastrectomy 1</title>
            <description>Propofol Dexmedetomidine Remifentanil&#xD;
Propofol: Total intravenous anaesthesia.&#xD;
Remifentanil: Narcotics&#xD;
Dexmedetomidine: Total intravenous anaesthesia</description>
          </group>
          <group group_id="O2">
            <title>Sleeve Gastrectomy 2</title>
            <description>Desflurane Remifentanil&#xD;
Remifentanil: Narcotics&#xD;
Desflurane: Inhalation anaesthesia.</description>
          </group>
        </group_list>
        <measure>
          <title>The Intra-operative Mean Arterial Blood Pressure.</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.05" spread="3.06"/>
                    <measurement group_id="O2" value="62.7" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During operation and follow-up, an average of 2 hours</time_frame>
      <desc>Nausea and vomiting</desc>
      <group_list>
        <group group_id="E1">
          <title>Intravenous Anaesthesia</title>
          <description>Propofol Dexmedetomidine Remifentanil&#xD;
Propofol: Total intravenous anaesthesia.&#xD;
Remifentanil: Narcotics&#xD;
Dexmedetomidine: Total intravenous anaesthesia</description>
        </group>
        <group group_id="E2">
          <title>Inhalation Anaesthesia</title>
          <description>Desflurane Remifentanil&#xD;
Remifentanil: Narcotics&#xD;
Desflurane: Inhalation anaesthesia.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Ezzeldin Ibrahim</name_or_title>
      <organization>Menoufia Univeristy</organization>
      <phone>0021006303178</phone>
      <email>ezzeldin7@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

